"On September 28, 2023, Qingdao Baheal Pharmaceutical Co., Ltd., a subsidiary of Shanghai Baheal Medical Co., Ltd., officially held a groundbreaking ceremony for the third phase of its production workshop and supporting construction projects. The event was attended by representative leaders from Jimo District Government of Qingdao city, provincial drug administration, Chairman Fu Gang of Baheal Pharma Group, General Manager Zhuo Yueqiang of Shanghai Xinchangning Group, directors of Baheal Pharma Group, and Zhu Xiaowei, Chairman of BAHEAL Pharmaceutical Co., Ltd. among other distinguished guests, as well as contractors and employees of Qingdao Baheal BAHEAL Pharmaceutical Co., LTD.

The new expansion of Qingdao Baheal Pharmaceutical Co., LTD production workshop and supporting projects for the third stage covers a total construction area of over 28,000 square meters. The project's main buildings include a formulation workshop, a comprehensive building, and a hazardous chemicals warehouse. Once completed, the project is expected to provide a drug production capacity of 5.6 billion tablets/pills for Baheal Pharmaceutical Co., LTD over the next decade.

At the ceremony, Ma Mingqiang, the Deputy District Head of Jimo District, Qingdao City, expressed his congratulations on the commencement of the third phase construction. He acknowledged that Qingdao Baheal Pharmaceutical Co., LTD has consistently made significant contributions to the high-quality development of the biopharmaceutical industry in Qingdao and Jimo District. With the further expansion of Qingdao Baheal Pharmaceutical Co., LTD's production capabilities, it is expected to vigorously drive the regional biopharmaceutical industry to upgrade and accelerate while injecting new vitality and momentum into the high-quality economic development

       "Fu Gang, Chairman of Baheal Pharma Group, stated that Qingdao Baheal Pharmaceutical Co. LTD., an innovative company characterized by advanced sustained-release formulation technology, is consistently devoted to the research and manufacturing of genuinely clinically valuable innovative products. At present, Qingdao Baheal Pharmaceutical Co., LTD is working closely with research institutes to explore source innovation and develop more innovative products. He expressed his hope that Baheal Pharmaceutical Co., LTD will seize this opportunity to grasp the dual opportunities of "innovation" and "creation" in China's pharmaceutical industry, continuously expand and dig deeper with technological innovation to optimize medical scenarios and serve human health more effectively.

Zhu Xiaowei, Chairman of Baheal Pharmaceutical Co., LTD, noted that Baheal Pharmaceutical Co., LTD, as a new force in China's ethnic pharmaceutical industry, is continually focused on making breakthroughs in the field of intractable disease treatment. He mentioned that they now have several innovative traditional Chinese medicine products and high-end dosage forms with strong innovation and independent intellectual property rights. The expansion of Qingdao Baheal Pharmaceutical Co., LTD marks the company's entry into a new stage of development and will bring internationally-standard products to more patients.

Qingdao Baheal Pharmaceutical Co., LTD, as a high-end sustained-release formulation research and manufacturing platform under Baheal Pharma Group, focuses on the R&D, production, and sales of advanced sustained-release formulations such as osmotic pumps, micro pellet coating, and skeletal tablets. Having passed the US FDA's cGMP inspection flawlessly, various products have accomplished simultaneous reporting and marketing in both China and the US. Prior to this, Qingdao Baheal Pharma's osmotic pump controlled-release metformin hydrochloride has been included in the national medical insurance; several products such as celecoxib capsule Nedachi, duloxetine hydrochloride enteric capsule Nashu, nifedipine sustained-release tablet Nate, and mecamylamine hydrochloride sustained-release capsule Naxin have also been selected for national procurement.

With this expansion as the opportunity, Qingdao Baheal Pharmaceutical Co., LTD will continuously expand and intensively cultivate in the fields of high-end preparations and original new drugs. Relying on their barrier technical strength, they plan to develop more innovative products. They also aim to support innovative developments in pharmaceutical research and development while enabling more patients to enjoy international standard high-end preparations, thus making more significant contributions to local economic and social development